FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591102840> ?p ?o ?g. }

• W2591102840 abstract "Abstract Abstract 758 The immunosuppressive nature of the tumor microenvironment may limit the efficacy of immunotherapy for patients with follicular lymphoma (FL). We previously showed that FL infiltrating T-cells (FL-T) are hypo-responsive to potent stimulation with plate bound anti-CD3/anti-CD28 antibodies as determined by proliferation and cytokine production. We showed that one mechanism for hypo-responsiveness was suppression by infiltrating CD4+CD25HIGITR+ regulatory T-cells (Hilchey et al. J. Immunol. (2007) 178:4051-61). Here we identify an additional novel mediator of FL-T hypo-responsiveness: pericellular adenosine, generated through the hydrolysis of extracellular ATP, and mediating its effects through interaction with FL-T associated A2A/B adenosine receptors (AR). We show that FL-T hypo-responsiveness is attenuated in a subset of FL patient samples by blocking the A2A/B, but not the A1 AR. Specifically, treatment of lymph node mononuclear cells (LNMC) derived from FL biopsy specimens with the specific A2A/B AR antagonist SCH58261 results in an increase in IFN-g and/or IL-2 secretion upon soluble anti-CD3/anti-CD28 antibody stimulation (in 3 of 6 patient samples tested), whereas treatment with an A1 AR antagonist, CPX, had no effect on cytokine secretion. In contrast to that seen with FL LNMC, SCH58261 treatment of stimulated LNMC derived from normal lymph nodes (NLN; n=5) had no effect on IFN-g and/or IL-2 secretion. As the rate limiting step for adenosine generation from pericellular ATP is the ectoATPase CD39, we next determined the effect of inhibiting CD39 activity on stimulated FL-T cytokine production. Inhibiting CD39 function with the selective CD39 antagonist ARL 67156, partially overcomes FL-T hypo-responsiveness in a subset of patient samples (2 of the 5 patient samples tested). Given the pivotal role that CD39 plays in the ATP-CD39-adenosine-A2AR pathway, we next determined whether the frequency of CD39 bearing T-cell populations differed in FL nodes as compared to that seen in NLN, reactive lymph nodes (RLN), or normal donor peripheral blood (PBMC), using 12 color flow cytometry. We show that CD4+CD39+ and CD8+CD39+ T-cell populations are overrepresented in FL as compared to that seen in NLN. In addition, 30% of the FL CD4+CD39+ T-cells have a regulatory T-cell (Treg) phenotype, co-expressing CD25HI and FOXP3 suggesting that the increased numbers of CD4+CD39+ T-cells observed within FL, as compared to NLN or RLN, are accounted for in part by the increased numbers of Tregs infiltrating the FL. Finally we show that the FL and NLN T-cell associated CD39 is functional, as it hydrolyzes ATP in vitro, in a dose and time dependent fashion. Taken together, the data suggest that the ATP-CD39-adenosine-A2AR pathway is one mechanism for T-cell hypo-responsiveness in FL. Indeed, to our knowledge, this is the first demonstration that this pathway is immunologically significant in any human tumor. The data also suggest that pharmacological inhibition of CD39 ecto-ATP-diphosphohydrolase activity, and/or blockade of the adenosine-A2AR interaction may be rationale strategies to enhance the efficacy of immunotherapeutic treatment approaches for patients with FL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2591102840 created "2017-03-03" @default.
• W2591102840 creator A5007088786 @default.
• W2591102840 creator A5008772684 @default.
• W2591102840 creator A5047882526 @default.
• W2591102840 creator A5050355532 @default.
• W2591102840 creator A5061370945 @default.
• W2591102840 creator A5069230555 @default.
• W2591102840 creator A5078753422 @default.
• W2591102840 creator A5080986767 @default.
• W2591102840 creator A5081803429 @default.
• W2591102840 creator A5088517954 @default.
• W2591102840 date "2009-11-20" @default.
• W2591102840 modified "2023-09-27" @default.
• W2591102840 title "Increased Proportions of CD39+ Infiltrating T-Cells Contribute to Adenosine Mediated T-Cell Hypo-Responsiveness within Human Follicular Lymphoma." @default.
• W2591102840 doi "https://doi.org/10.1182/blood.v114.22.758.758" @default.
• W2591102840 hasPublicationYear "2009" @default.
• W2591102840 type Work @default.
• W2591102840 sameAs 2591102840 @default.
• W2591102840 citedByCount "0" @default.
• W2591102840 crossrefType "journal-article" @default.
• W2591102840 hasAuthorship W2591102840A5007088786 @default.
• W2591102840 hasAuthorship W2591102840A5008772684 @default.
• W2591102840 hasAuthorship W2591102840A5047882526 @default.
• W2591102840 hasAuthorship W2591102840A5050355532 @default.
• W2591102840 hasAuthorship W2591102840A5061370945 @default.
• W2591102840 hasAuthorship W2591102840A5069230555 @default.
• W2591102840 hasAuthorship W2591102840A5078753422 @default.
• W2591102840 hasAuthorship W2591102840A5080986767 @default.
• W2591102840 hasAuthorship W2591102840A5081803429 @default.
• W2591102840 hasAuthorship W2591102840A5088517954 @default.
• W2591102840 hasConcept C126322002 @default.
• W2591102840 hasConcept C134018914 @default.
• W2591102840 hasConcept C148125776 @default.
• W2591102840 hasConcept C185592680 @default.
• W2591102840 hasConcept C203014093 @default.
• W2591102840 hasConcept C2776090121 @default.
• W2591102840 hasConcept C2776991684 @default.
• W2591102840 hasConcept C2777058707 @default.
• W2591102840 hasConcept C2778690821 @default.
• W2591102840 hasConcept C2779338263 @default.
• W2591102840 hasConcept C71924100 @default.
• W2591102840 hasConcept C79484868 @default.
• W2591102840 hasConcept C86803240 @default.
• W2591102840 hasConcept C8891405 @default.
• W2591102840 hasConceptScore W2591102840C126322002 @default.
• W2591102840 hasConceptScore W2591102840C134018914 @default.
• W2591102840 hasConceptScore W2591102840C148125776 @default.
• W2591102840 hasConceptScore W2591102840C185592680 @default.
• W2591102840 hasConceptScore W2591102840C203014093 @default.
• W2591102840 hasConceptScore W2591102840C2776090121 @default.
• W2591102840 hasConceptScore W2591102840C2776991684 @default.
• W2591102840 hasConceptScore W2591102840C2777058707 @default.
• W2591102840 hasConceptScore W2591102840C2778690821 @default.
• W2591102840 hasConceptScore W2591102840C2779338263 @default.
• W2591102840 hasConceptScore W2591102840C71924100 @default.
• W2591102840 hasConceptScore W2591102840C79484868 @default.
• W2591102840 hasConceptScore W2591102840C86803240 @default.
• W2591102840 hasConceptScore W2591102840C8891405 @default.
• W2591102840 hasLocation W25911028401 @default.
• W2591102840 hasOpenAccess W2591102840 @default.
• W2591102840 hasPrimaryLocation W25911028401 @default.
• W2591102840 hasRelatedWork W1605448181 @default.
• W2591102840 hasRelatedWork W1957293994 @default.
• W2591102840 hasRelatedWork W1965586982 @default.
• W2591102840 hasRelatedWork W1975440932 @default.
• W2591102840 hasRelatedWork W2078573471 @default.
• W2591102840 hasRelatedWork W2114002084 @default.
• W2591102840 hasRelatedWork W2114990377 @default.
• W2591102840 hasRelatedWork W2301114920 @default.
• W2591102840 hasRelatedWork W2526420665 @default.
• W2591102840 hasRelatedWork W2583222213 @default.
• W2591102840 hasRelatedWork W2607979884 @default.
• W2591102840 hasRelatedWork W2902658872 @default.
• W2591102840 hasRelatedWork W2975590727 @default.
• W2591102840 hasRelatedWork W2979794993 @default.
• W2591102840 hasRelatedWork W3006614976 @default.
• W2591102840 hasRelatedWork W3104499934 @default.
• W2591102840 hasRelatedWork W3127857896 @default.
• W2591102840 hasRelatedWork W3128231733 @default.
• W2591102840 hasRelatedWork W3206065813 @default.
• W2591102840 hasRelatedWork W3120265144 @default.
• W2591102840 isParatext "false" @default.
• W2591102840 isRetracted "false" @default.
• W2591102840 magId "2591102840" @default.
• W2591102840 workType "article" @default.